Meeting
2021 ASCO Annual Meeting
Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.
Authors
Ramaswamy Govindan
Washington University School of Medicine, St. Louis, MO
Ramaswamy Govindan , Amanda Rose Townsend , Kathy D. Miller , Inderjit Mehmi , Yasutoshi Kuboki , Ecaterina Elena Dumbrava , Erika P. Hamilton , Irene Vuu , Erik Rasmussen , Linda R. Mileshkin , Sofia Genta , Hiroji Iwata , Sylvia Adams , Hisaki Fujii , Sant P. Chawla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04293094
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5600)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5600
Abstract #
TPS5600
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.
First Author: Kaiwen Li
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang
Poster
2022 ASCO Annual Meeting
A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.
First Author: Kyriakos P. Papadopoulos
First Author: R. Wendel Naumann